Lucid Diagnostics Inc., a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., has announced the closing of an underwritten public offering of 28,750,000 shares of its common stock at a price of $1.00 per share. This includes the full exercise of the underwriters' option to purchase an additional 3,750,000 shares. The offering is expected to yield net proceeds of approximately $26.9 million after expenses. The company plans to utilize these funds for working capital and general corporate purposes. Canaccord Genuity LLC and BTIG, LLC served as joint bookrunners, with Maxim Group LLC acting as co-manager. The securities were offered under a shelf registration statement declared effective by the SEC on December 6, 2022. The prospectus supplement and accompanying base prospectus were filed with the SEC on September 10, 2025. Copies of the prospectus are available from Canaccord Genuity LLC and BTIG, LLC.